EcoDrugPlus

Glycogen Synthase Kinase 3 Alpha B

Ensembl ID : ENSCCRG00000005989
Gene Symbol: GSK3AB
1 Cross references
182 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta, Genome Duplicate A

Ensembl ID : ENSCCRG00000019917
Gene Symbol: GSK3BA
1 Cross references
206 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta, Genome Duplicate A

Ensembl ID : ENSCCRG00000013021
Gene Symbol: GSK3BA
1 Cross references
206 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta, Genome Duplicate B

Ensembl ID : ENSCCRG00000076785
Gene Symbol: GSK3BB
1 Cross references
161 Possible Orthologues:

Growth Hormone Secretagogue Receptor A

Ensembl ID : ENSCCRG00000009349
Gene Symbol: GHSRA
1 Cross references
193 Possible Orthologues:

Growth Hormone Secretagogue Receptor A

Ensembl ID : ENSCCRG00000073726
Gene Symbol: GHSRA
1 Cross references
193 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSCCRG00000022620
Gene Symbol: GUCY1A1
1 Cross references
198 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSCCRG00000028759
Gene Symbol: GUCY1A1
1 Cross references
199 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSCCRG00000069969
Gene Symbol: GUCY1A2
1 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSCCRG00000070908
Gene Symbol: GUCY1A2
1 Cross references
200 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSCCRG00000018176
Gene Symbol: GUCY1B1
1 Cross references
207 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSCCRG00000022330
Gene Symbol: GUCY1B1
1 Cross references
208 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).